JP2025500347A5 - - Google Patents

Info

Publication number
JP2025500347A5
JP2025500347A5 JP2024537381A JP2024537381A JP2025500347A5 JP 2025500347 A5 JP2025500347 A5 JP 2025500347A5 JP 2024537381 A JP2024537381 A JP 2024537381A JP 2024537381 A JP2024537381 A JP 2024537381A JP 2025500347 A5 JP2025500347 A5 JP 2025500347A5
Authority
JP
Japan
Prior art keywords
optionally
polypeptide
aav
disease
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077628 external-priority patent/WO2023060142A2/en
Publication of JP2025500347A publication Critical patent/JP2025500347A/ja
Publication of JP2025500347A5 publication Critical patent/JP2025500347A5/ja
Pending legal-status Critical Current

Links

JP2024537381A 2021-10-05 2022-10-05 操作された心筋組成物 Pending JP2025500347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252559P 2021-10-05 2021-10-05
US63/252,559 2021-10-05
PCT/US2022/077628 WO2023060142A2 (en) 2021-10-05 2022-10-05 Engineered cardiac muscle compositions

Publications (2)

Publication Number Publication Date
JP2025500347A JP2025500347A (ja) 2025-01-09
JP2025500347A5 true JP2025500347A5 (cg-RX-API-DMAC7.html) 2025-10-15

Family

ID=85803752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537381A Pending JP2025500347A (ja) 2021-10-05 2022-10-05 操作された心筋組成物

Country Status (7)

Country Link
US (1) US20240409956A1 (cg-RX-API-DMAC7.html)
EP (1) EP4413025A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025500347A (cg-RX-API-DMAC7.html)
CN (1) CN118339176A (cg-RX-API-DMAC7.html)
AU (1) AU2022360985A1 (cg-RX-API-DMAC7.html)
CA (1) CA3236534A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023060142A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3210955A1 (en) * 2021-02-09 2022-08-18 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
WO2025024254A2 (en) * 2023-07-21 2025-01-30 The Trustees Of Indiana University Aav vector formulation
EP4766844A1 (en) * 2023-08-25 2026-07-01 Agency for Science, Technology And Research COMPOSITION AND METHODS FOR IDENTIFYING NEW AAV VARIANTS FOR ADMINISTRATING DIFFERENTIATED GENES TO CARDIOMYOCTS AND/OR SKELETAL MYOFIBERS
WO2025160155A1 (en) 2024-01-22 2025-07-31 The Broad Institute, Inc. Epigenetic targeting of prion diseases
WO2026006391A1 (en) * 2024-06-25 2026-01-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for treating a heart disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2006092449A2 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
DK3684423T5 (da) * 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
US11149256B2 (en) * 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3883591B1 (en) * 2018-11-20 2024-11-13 Universität Heidelberg Relaxin receptor 1 for use in treatment and prevention of heart failure
US20220325296A1 (en) * 2019-09-12 2022-10-13 The Broad Institute, Inc. Engineered adeno-associated virus capsids
JP2022551986A (ja) * 2019-10-16 2022-12-14 ザ・ブロード・インスティテュート・インコーポレイテッド 修飾筋肉標的化組成物
EP3868875A1 (en) * 2020-02-20 2021-08-25 Medizinische Hochschule Hannover Viral vector particle based on aav2 for gene therapy

Similar Documents

Publication Publication Date Title
JP2023534999A5 (cg-RX-API-DMAC7.html)
JP2022551986A5 (cg-RX-API-DMAC7.html)
JP2023524061A5 (cg-RX-API-DMAC7.html)
US20240197918A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
JP2024530023A5 (cg-RX-API-DMAC7.html)
JP6174318B2 (ja) アデノ随伴ウイルス構築物を含んでなるコンダクティング気道細胞を標的とするための組成物
JP2024514956A5 (cg-RX-API-DMAC7.html)
JP2024099770A5 (cg-RX-API-DMAC7.html)
JP2024009857A5 (cg-RX-API-DMAC7.html)
JP2021512649A5 (cg-RX-API-DMAC7.html)
IL273261B2 (en) Adeno-associated virus variant capsids and methods of using them
JP2022547197A5 (cg-RX-API-DMAC7.html)
CN116096431A (zh) 肽修饰的aav衣壳
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2023514242A5 (cg-RX-API-DMAC7.html)
JP2023537358A5 (cg-RX-API-DMAC7.html)
JP2021520837A5 (cg-RX-API-DMAC7.html)
JP2021534766A5 (cg-RX-API-DMAC7.html)
JP2003526377A (ja) キメラキャプシドベクターの製造
JP2023551873A5 (cg-RX-API-DMAC7.html)
JP2022551744A5 (cg-RX-API-DMAC7.html)
JP2025517628A5 (cg-RX-API-DMAC7.html)
EP3952920A1 (en) Hybrid promoters for muscle expression
EP4717715A1 (en) Adeno-associated virus capsid protein, adeno-associated virus containing same, vector and use thereof
JP2022533448A5 (cg-RX-API-DMAC7.html)